The Latest From CureMatch
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found. The findings were reported at the virtual Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020). Clinical trials evaluated were listed on ClinicalTrials.gov between January 1, 2019, and […]
PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a leader in digital health precision medicine today announced that they have received CE Mark approval for Bionov™, their professional-use clinical decision support software…. read more See full article here
Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient outcomes and quality of life. Plus, it’s enrollment season! Get the information you need for Medicare enrollment in this week’s conversation with Samantha Smith from the Patients Rising Concierge. And as November marks Lung Cancer Awareness Month, Terry and Dr. […]
Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to identify candidate protease inhibitors for COVID-19 SAN DIEGO, CA – April 15, 2020 – CureMatch, a digital health company focusing on personalized medicine and combination therapies, today announced that Chief Science Officer and Co-Founder, Dr. Igor Tsigelny, along with Dr. […]
Navid Alipour, founder of our parent company, Analytics Ventures, was interviewed by AI Trends regarding the challenges of using artificial intelligence in healthcare–and how we at CureMatch are working to solve those challenges. Read the full article here.